AI English summary of an SEC filing — figures as filed
Zimmer Biomet ZBHThe company said its net sales for Q2 2024 were $1.942 billion, up 3.9% from the prior year period, and rose 5.6% on a constant currency basis.
Key points
AI summaryThe company said its net sales for Q2 2024 were $1.942 billion, up 3.9% from the prior year period, and rose 5.6% on a constant currency basis.
The company said net earnings attributable to Zimmer Biomet for Q2 were $242.8 million, with diluted earnings per share of $1.18. On an adjusted basis, net earnings were $415.0 million and adjusted diluted earnings per share were $2.01.
The company said it changed its full-year 2024 reported revenue change outlook to 4.0% to 5.0% from 4.5% to 5.5%, and changed its foreign currency exchange impact assumption to (0.5)% from (1.0)%. It said it kept its constant currency revenue growth of 5.0% to 6.0% and its adjusted diluted EPS of $8.00 to $8.15 unchanged.
The company said net cash provided by operating activities was $597.4 million for the 6 months ended June 30, and free cash flow for Q2 was $251.5 million, compared with $165.3 million a year earlier.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Zimmer Biomet Q2 Net Sales $1.942 billion
The company said its net sales for Q2 2024 were $1.942 billion, up 3.9% from the prior year period, and rose 5.6% on a constant currency basis.
Source · Based on the filing body and exhibits
Zimmer Biomet Q2 Net Earnings and EPS
The company said net earnings attributable to Zimmer Biomet for Q2 were $242.8 million, with diluted earnings per share of $1.18. On an adjusted basis, net earnings were $415.0 million and adjusted diluted earnings per share were $2.01.
Source · Based on the filing body and exhibits
Zimmer Biomet Changes Reported Revenue Outlook for Year
The company said it changed its full-year 2024 reported revenue change outlook to 4.0% to 5.0% from 4.5% to 5.5%, and changed its foreign currency exchange impact assumption to (0.5)% from (1.0)%. It said it kept its constant currency revenue growth of 5.0% to 6.0% and its adjusted diluted EPS of $8.00 to $8.15 unchanged.
Source · Based on the filing body and exhibits
Zimmer Biomet 6-Month Operating Cash Flow and Q2 Free Cash Flow
The company said net cash provided by operating activities was $597.4 million for the 6 months ended June 30, and free cash flow for Q2 was $251.5 million, compared with $165.3 million a year earlier.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…